Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer's disease

Ziwei Chen, Maria Digiacomo, Yalin Tu, Qiong Gu, Shengnan Wang, Xiaohong Yang, Jiaqi Chu, Qiuhe Chen, Yifan Han, Jingkao Chen, Giulia Nesi, Simona Sestito, Marco Macchia, Simona Rapposelli, Rongbiao Pi

Research output: Journal article publicationJournal articleAcademic researchpeer-review

35 Citations (Scopus)


The new compounds exerted antioxidant neuroprotective properties and good cholinesterases (ChE) inhibitory activities. Some of them also inhibited amyloid protein (Aβ) aggregation. In particular, compound 5 emerged as promising drug candidates endowed with neuroprotective potential, ChE inhibitory, Aβ self-aggregation inhibitory and copper chelation properties. These data suggest that compound 5 offers an attractive starting point for further lead optimization in the drug-discovery process against AD.
Original languageEnglish
Pages (from-to)784-792
Number of pages9
JournalEuropean Journal of Medicinal Chemistry
Publication statusPublished - 1 Jan 2017


  • Alzheimer's disease
  • Caffeic acid
  • Ferulic acid
  • Hybrid
  • Multifunctional agents
  • Rivastigmine

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this